Magrolimab is a first-in-class CD47 inhibitor antibody that has been shown basically to induce complete responses in a significant number of patients with higher-risk MDS once combined with azacitidine. And of course we have now ongoing randomized study to confirm those results called the Enhance trial. And we also have an oral version of decitabine and that’s already approved, which is a combination of decitabine with cedazuridine so that it can be taken orally...
Magrolimab is a first-in-class CD47 inhibitor antibody that has been shown basically to induce complete responses in a significant number of patients with higher-risk MDS once combined with azacitidine. And of course we have now ongoing randomized study to confirm those results called the Enhance trial. And we also have an oral version of decitabine and that’s already approved, which is a combination of decitabine with cedazuridine so that it can be taken orally. So with those two pieces of data, we decided to conduct a trial that combines Magrolimab with the oral decitabine and cedazuridine. So this will be a Phase II study, it’s going to be international – run in many countries – and it’s going to look, as a primary endpoint, at the response rate. But of course we are going to look at other endpoints, including survival outcomes. We are very excited with this study and it’s going to open hopefully in the next couple of weeks for enrolment.